- Home
- MNY vs ELOX Comparison
MNY vs ELOX Comparison
Compare MNY & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MNY | ELOX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Singapore | United States |
| Employees | 240 | 7 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 43.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MNY | ELOX |
|---|---|---|
| Price | $0.94 | $11.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 65.3K | 42.4K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $10.00 |
| 52 Week High | $2.40 | $15.00 |
Technical Indicators
Market Signals| Indicator | MNY | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 43.01 |
| Support Level | $0.78 | $10.51 |
| Resistance Level | $1.03 | $14.50 |
| Average True Range (ATR) | 0.07 | 2.18 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 64.00 | 32.74 |
Price Performance
Historical ComparisonAbout MNY MoneyHero Limited
MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.